PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY- A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66792-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)66792-7/fulltext
Title :
PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY- A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66792-7&doi=10.1016/S1098-3015(10)66792-7
First page :
Section Title :
Open access? :
No
Section Order :
627